[go: up one dir, main page]

AR124227A1 - Oligonucleótidos antisentido que actúan sobre atxn3 - Google Patents

Oligonucleótidos antisentido que actúan sobre atxn3

Info

Publication number
AR124227A1
AR124227A1 ARP210103342A ARP210103342A AR124227A1 AR 124227 A1 AR124227 A1 AR 124227A1 AR P210103342 A ARP210103342 A AR P210103342A AR P210103342 A ARP210103342 A AR P210103342A AR 124227 A1 AR124227 A1 AR 124227A1
Authority
AR
Argentina
Prior art keywords
compound
seq
atxn3
nucleoside
lna
Prior art date
Application number
ARP210103342A
Other languages
English (en)
Inventor
Heidi Rye Hudlebusch
Alexander Herbert Stephan
Lykke Pedersen
Christoffer Sondergaard
Erik Funder
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR124227A1 publication Critical patent/AR124227A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a oligonucleótidos antisentido de LNA (oligómeros) complementarios de secuencias de pre-mARN de ATXN3, que son capaces de inhibir la expresión de proteína de ATNX3. La inhibición de la expresión de ATXN3 es beneficiosa para el tratamiento de la ataxia espinocerebelosa. Reivindicación 1: Un oligonucleótido antisentido seleccionado del grupo que consiste en compuestos ID Nº 1605_2, 1605_4, 1605_3, 1605_5, 1605_23, 1809_8, 1810_39, 1812_4, 1813_4, 1813_15 y 1813_16; o una sal de este aceptable desde el punto de vista farmacéutico. Reivindicación 2: Un oligonucleótido antisentido de acuerdo con la siguiente anotación química: a) [LR]T[ₛP]×[LR][⁵ᵐᵉ]C[ₛP]×[ᵈR]T[ₛP]×[LR]T[ₛP]×[ᵈR]C[ₛP]×[LR]A[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]C[ₛP]×[ᵈR]C[ₛP]×[ᵈR]A[ₛP]×[ᵈR]T[ₛP]×[LR][⁵ᵐᵉ]C[ₛP]×[LR]A[ₛP]×[LR]A (SEQ ID Nº 1605) (compuesto ID Nº 1605_2); b) [LR]T[ₛP]×[LR][⁵ᵐᵉ]C[ₛP]×[ᵈR]T[ₛP]×[LR]T[ₛP]×[ᵈR]C[ₛP]×[ᵈR]A[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]C[ₛP]×[ᵈR]C[ₛP]×[LR]A[ₛP]×[ᵈR]T[ₛP]×[LR][⁵ᵐᵉ]C[ₛP]×[LR]A[ₛP]×[LR]A (SEQ ID Nº 1605) (compuesto ID Nº 1605_4); c) [LR]T[ₛP]×[LR][⁵ᵐᵉ]C[ₛP]×[ᵈR]T[ₛP]×[LR]T[ₛP]×[ᵈR]C[ₛP]×[ᵈR]A[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]C[ₛP]×[ᵈR]C[ₛP]×[ᵈR]A[ₛP]×[ᵈR]T[ₛP]×[LR][⁵ᵐᵉ]C[ₛP]×[LR]A[ₛP]×[LR]A (SEQ ID Nº 1605) (compuesto ID Nº 1605_3); d) [LR]T[ₛP]×[LR][⁵ᵐᵉ]C[ₛP]×[LR]T[ₛP]×[ᵈR]T[ₛP]×[LR][⁵ᵐᵉ]C[ₛP]×[ᵈR]A[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]C[ₛP]×[ᵈR]C[ₛP]×[ᵈR]A[ₛP]×[LR]T[ₛP]×[LR][⁵ᵐᵉ]C[ₛP]×[LR]A[ₛP]×[LR]A (SEQ ID Nº 1605) (compuesto ID Nº 1605_5); e) [LR]T[ₛP]×[LR][⁵ᵐᵉ]C[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[LR][⁵ᵐᵉ]C[ₛP]×[ᵈR]A[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]C[ₛP]×[ᵈR]C[ₛP]×[LR]A[ₛP]×[LR]T[ₛP]×[ᵈR]C[ₛP]×[LR]A[ₛP]×[LR]A (SEQ ID Nº 1605) (compuesto ID Nº 1605_23); f) [LR]G[ₛP]×[LR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]C[ₛP]×[LR]A[ₛP]×[ᵈR]C[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]C[ₛP]×[LR]A[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]C[ₛP]×[LR][⁵ᵐᵉ]C[ₛP]×[LR][⁵ᵐᵉ]C (SEQ ID Nº 1809) (compuesto ID Nº 1809_8); g) [LR]T[ₛP]×[LR]A[ₛP]×[ᵈR]C[ₛP]×[LR]A[ₛP]×[ᵈR]C[ₛP]×[LR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]C[ₛP]×[ᵈR]A[ₛP]×[ᵈR]T[ₛP]×[LR]T[ₛP]×[ᵈR]C[ₛP]×[LR][⁵ᵐᵉ]C[ₛP]×[LR][⁵ᵐᵉ]C (SEQ ID Nº 1810) (compuesto ID Nº 1810_39); h) [LR]T[ₛP]×[LR]G[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]C[ₛP]×[ᵈR]A[ₛP]×[ᵈR]C[ₛP]×[LR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]C[ₛP]×[ᵈR]A[ₛP]×[ᵈR]T[ₛP]×[LR]T[ₛP]×[LR][⁵ᵐᵉ]C[ₛP]×[LR][⁵ᵐᵉ]C (SEQ ID Nº 1812) (compuesto ID Nº 1812_4); i) [LR][⁵ᵐᵉ]C[ₛP]×[LR]T[ₛP]×[LR]G[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]C[ₛP]×[LR]A[ₛP]×[ᵈR]C[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]C[ₛP]×[ᵈR]A[ₛP]×[LR]T[ₛP]×[LR]T[ₛP]×[LR][⁵ᵐᵉ]C (SEQ ID Nº 1813) (compuesto ID Nº 1813_4); j) [LR][⁵ᵐᵉ]C[ₛP]×[LR]T[ₛP]×[LR]G[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵐR]C[ₛP]×[ᵐR]A[ₛP]×[ᵈR]C[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]C[ₛP]×[ᵈR]A[ₛP]×[LR]T[ₛP]×[LR]T[ₛP]×[LR][⁵ᵐᵉ]C (SEQ ID Nº1813) (compuesto ID Nº 1813_15); o k) [LR][⁵ᵐᵉ]C[ₛP]×[LR]T[ₛP]×[LR]G[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵐR]C[ₛP]×[ᵈR]A[ₛP]×[ᵐR]C[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]T[ₛP]×[ᵈR]A[ₛP]×[ᵈR]C[ₛP]×[ᵈR]A[ₛP]×[LR]T[ₛP]×[LR]T[ₛP]×[LR][⁵ᵐᵉ]C (SEQ ID Nº 1813) (compuesto ID Nº 1813_16); o una sal de este aceptable desde el punto de vista farmacéutico, en donde [LR] es un nucleósido de b-D-oxi-LNA, [LR][5me]C es un nucleósido de b-D-oxi-LNA 5-metil citosina, [dR] es un nucleósido de ADN, [sP] es un enlace internucleosídico fosforotioato (estereoindefinido), y [mR] es un nucleósido de 2’-O-metilo.
ARP210103342A 2020-12-03 2021-12-02 Oligonucleótidos antisentido que actúan sobre atxn3 AR124227A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20211623 2020-12-03

Publications (1)

Publication Number Publication Date
AR124227A1 true AR124227A1 (es) 2023-03-01

Family

ID=73698681

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103342A AR124227A1 (es) 2020-12-03 2021-12-02 Oligonucleótidos antisentido que actúan sobre atxn3

Country Status (4)

Country Link
US (1) US20230060373A1 (es)
AR (1) AR124227A1 (es)
TW (1) TW202237843A (es)
WO (1) WO2022117747A2 (es)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
ATE293123T1 (de) 1997-09-12 2005-04-15 Exiqon As Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
CA2361318C (en) 1999-02-12 2008-11-25 Sankyo Company, Limited Novel nucleosides and oligonucleotide analogues
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
AU2003281969B2 (en) 2002-11-18 2011-01-27 Roche Innovation Center Copenhagen A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
ES2516815T3 (es) 2006-01-27 2014-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en la posición 6
CN101490074B (zh) 2006-05-11 2013-06-26 Isis制药公司 5’-修饰的双环核酸类似物
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
ATE540118T1 (de) 2006-10-18 2012-01-15 Isis Pharmaceuticals Inc Antisense-verbindungen
ES2388590T3 (es) 2007-05-30 2012-10-16 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos con puente aminometileno N-sustituido.
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
EP2176280B2 (en) 2007-07-05 2015-06-24 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
WO2011017521A2 (en) 2009-08-06 2011-02-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US10017764B2 (en) 2011-02-08 2018-07-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US20150051389A1 (en) 2011-08-11 2015-02-19 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
US20150315595A1 (en) * 2012-03-12 2015-11-05 Santaris Pharma A/S Compositions and Methods for Modulation of ATXN3 Expression
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
JP2016503300A (ja) 2012-11-15 2016-02-04 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ 抗ＡｐｏＢアンチセンス複合体化合物
US10435430B2 (en) 2013-07-31 2019-10-08 Ionis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
EP3099797B1 (en) 2014-01-30 2019-08-21 F. Hoffmann-La Roche AG Poly oligomer compound with biocleavable conjugates
RU2017127609A (ru) 2015-02-04 2019-03-04 Ф. Хоффманн-Ля Рош Аг Антисмысловые олигомеры тау-белка и их применение
US20180023081A1 (en) * 2015-02-04 2018-01-25 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
JOP20190104A1 (ar) * 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن atxn3
CN112189053B (zh) * 2018-05-09 2024-05-14 Ionis制药公司 用于减少atxn3表达的化合物和方法
JP2022520986A (ja) 2019-02-22 2022-04-04 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ａｔｘｎ３発現を減少させるための化合物及び方法
JP7155302B2 (ja) * 2019-06-06 2022-10-18 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘｎ３を標的とするアンチセンスオリゴヌクレオチド

Also Published As

Publication number Publication date
WO2022117747A2 (en) 2022-06-09
TW202237843A (zh) 2022-10-01
US20230060373A1 (en) 2023-03-02
WO2022117747A3 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
AU674158B2 (en) Hybrid oligonucleotide phosphorothioates
Dagle et al. Targeted degradation of mRNA in Xenopus oocytes and embryos directed by modified oligonucleotides: studies of An2 and cyclin in embryogenesis
US6013786A (en) MDM2-specific antisense oligonucleotides
ES2749374T3 (es) Compuestos inhibitorios dirigidos a conexina 43 y sus métodos de uso en el tratamiento del trauma ocular de la córnea
Sproat Chemistry and applications of oligonucleotide analogues
EP0649467B1 (en) Self-stabilized oligonucleotides as therapeutic agents
CA2520541A1 (en) Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field
Brysch et al. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents
WO1994002498A9 (en) Hybrid oligonucleotide phosphorothioates
JP2004507263A (ja) Ｖｒ１に対するアンチセンスオリゴヌクレオチド
CA2154578A1 (en) Oligonucleotide alkylphosphonates and alkylphosphonothioates
CA2526893A1 (en) Inhibition of the expression of huntingtin gene
KR20010020405A (ko) 키메라 및 교차 올리고뉴클레오티드를 갖는 ｒａｓ 유전자의 안티센스 저해
JP2016531570A (ja) ユークロマチン領域を標的とするオリゴヌクレオチド
PE20212131A1 (es) Compuestos y metodos para reducir de la expresion de atxn3
JP2015523853A5 (es)
Toulme et al. Targeting RNA structures by antisense oligonucleotides
JP2017528441A5 (es)
FI3717646T3 (fi) Angelmanin oireyhtymän antisense-hoito
Arzumanov et al. A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2′-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), α-L-LNA, or 2′-thio-LNA residues
CA2555463C (en) Inhibitors of tgf-r signaling for treatment of cns disorders
PE20201501A1 (es) Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos
AR124227A1 (es) Oligonucleótidos antisentido que actúan sobre atxn3
WO1992003455A1 (en) INHIBITION OF $i(CANDIDA)
AR124228A1 (es) Oligonucleótidos antisentido que actúan sobre atxn3

Legal Events

Date Code Title Description
FB Suspension of granting procedure